微脉冲联合迈之灵治疗中心性浆液性脉络膜视网膜病变的效果分析

Clinical efficacy of micropulse combined with Maizhiling in treatment of central serous chorioretinopathy

目的研究微脉冲联合迈之灵治疗中心性浆液性脉络膜视网膜病变疗效分析。方法选取100例来我院眼科就诊的中浆病患者,分别给予577 nm微脉冲激光联合迈之灵药物口服治疗(研究组)50例和单纯迈之灵口服50例(对照组),于初诊、治疗后1周、1个月、3个月、6个月分别行最佳矫正视力(BCVA)及OCT检查测量黄斑中心凹厚度(CMT)及黄斑中心凹6 mm内容积,观察视网膜下积液及视网膜色素上皮(RPE)损伤情况。结果治疗后,2组BCVA显著升高(P<0.05),CMT、中心凹6 mm容积均显著下降(P<0.05);研究组治疗后1周、1个月、3个月CMT、中心凹6 mm内容积水平低于对照组,差异有统计学意义(P<0.05)。结论577 nm微脉冲激光联合迈之灵口服可有效治疗中浆病(CSC),提高患者视力,改善视功能,且起效快,效果更好,具有很好的安全性和有效性,值得临床推广。

Objective To investigate the clinical effects of micropulse combined with Maizhiling in treatment of central serous chorioretinopathy(CSC).Methods A total of 100 patients with CSC who were treated in our hospital were enrolled in the study,who were given 577nm micropulse laser combined with oral medication Maizhiling(research group,n=50)or oral medication Maizhiling alone(control group).At initial diagnosis,at 1 week,1 month,3 months,and 6 months after treatment,the best corrected visual acuity(BCVA)and OCT were performed to measure central macular thickness(CMT)and the 6 mm inner volume of the macular central fovea,and the subretinal fluid and the damage of retinal pigment epithelium(RPE)was observed.Results After treatment,BCVA was significantly increased in both groups(P<0.05),while CMT and 6 mm volume of macular central fovea were significantly decreased(P<0.05).CMT and 6 mm volume of macular central fovea at 1w,1m,and 3m after treatment were significantly lower than those in control group(P<0.05).Conclusion The 577 nm micropulse laser combined with oral medication Maizhiling can be used to treat CSC effectively,which can improve patients’visual acuity and visual function,and has a fast onset of action,better effect as well as good safety and efficacy.Therefore,it is worthy of clinical promotion.